A single inhaler containing long-acting beta-2 agonist (LABA) and inhaled corticosteroid (ICS) might be the first step in mild asthma treatment instead of a short-acting beta agonist (SABA) for as-needed reliever therapy, a major study has shown. Findings from the Novel START trial, presented at the American Thoracic Society (ATS) annual meeting in Dallas, showed ...
Single ICS-LABA inhaler backed for mild asthma
By Michael Woodhead
21 May 2019